Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Shares Issued (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Shares Issued for 16 consecutive years, with $239000.0 as the latest value for Q4 2025.

  • Quarterly Shares Issued fell 19.53% to $239000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $500000.0 through Dec 2025, down 29.38% year-over-year, with the annual reading at $500000.0 for FY2025, 29.38% down from the prior year.
  • Shares Issued for Q4 2025 was $239000.0 at Anika Therapeutics, down from $261000.0 in the prior quarter.
  • The five-year high for Shares Issued was $665000.0 in Q4 2022, with the low at -$15000.0 in Q2 2022.
  • Average Shares Issued over 5 years is $216000.0, with a median of $176500.0 recorded in 2021.
  • The sharpest move saw Shares Issued crashed 102.33% in 2022, then skyrocketed 2221.43% in 2024.
  • Over 5 years, Shares Issued stood at $114000.0 in 2021, then skyrocketed by 483.33% to $665000.0 in 2022, then plummeted by 102.11% to -$14000.0 in 2023, then surged by 2221.43% to $297000.0 in 2024, then decreased by 19.53% to $239000.0 in 2025.
  • According to Business Quant data, Shares Issued over the past three periods came in at $239000.0, $261000.0, and $297000.0 for Q4 2025, Q3 2025, and Q4 2024 respectively.